The NSAID that displaced aspirin
Ibuprofen was synthesised in 1961 by Stewart Adams and John Nicholson at Boots in the UK while they were looking for an anti-inflammatory gentler on the stomach than aspirin. It was first sold on prescription in 1969 and over the counter from 1983, and today it is one of the most widely used drugs in the world, with annual production in the tens of thousands of tonnes.
Its central advantage over aspirin is the way it inhibits COX: ibuprofen is a reversible, competitive inhibitor, so the enzyme regains its activity as ibuprofen levels fall. That has important clinical consequences, especially for platelets.
Structure: a chiral propionic acid
Ibuprofen (2-(4-isobutylphenyl)propanoic acid, C₁₃H₁₈O₂) looks simple: a benzene ring with an isobutyl group in the para position and a propionic acid chain (–CH(CH₃)COOH) at position one.
The α carbon of the propionic chain is a stereocentre: it carries four different substituents. So there are two enantiomers:
- (S)-(+)-ibuprofen: the pharmacologically active form that inhibits COX
- (R)-(−)-ibuprofen: inactive against COX, but the body converts it enzymatically into the S form (a one-way chiral inversion by alpha-methylacyl-CoA racemase)
Commercial products contain the racemic mixture (50/50 R/S). Pure S-ibuprofen (dexibuprofen) acts slightly faster because it needs no chiral inversion, although conversion in the body makes the practical difference smaller than expected.
Reversible COX inhibition: the difference from aspirin
Unlike aspirin, ibuprofen does not acetylate the serine in COX. It simply occupies the hydrophobic channel of the active site through non-covalent interactions: its carboxylate forms an ion pair with Arg-120 and a hydrogen bond with Tyr-355 at the mouth of the channel, and the rest of the molecule settles in through hydrophobic contacts. When plasma ibuprofen falls, the enzyme is freed and becomes active again.
The most important clinical consequence: ibuprofen's effect on platelets is temporary. Within 24 hours of the last dose, platelet function has almost fully recovered. This contrasts sharply with aspirin, whose platelet inhibition lasts the platelet's whole life (8–10 days).
There is a relevant drug interaction: ibuprofen taken before aspirin competes for the same site on platelet COX-1, blocking aspirin's access and preventing its irreversible acetylation. Patients taking low-dose aspirin to prevent clots should not take ibuprofen regularly without medical advice, because it can cancel aspirin's protective effect on the heart.
COX-1 vs COX-2: ibuprofen is non-selective
Ibuprofen inhibits COX-1 and COX-2 to a similar degree (COX-1/COX-2 ratio ≈ 1). That explains both its anti-inflammatory power and its side effects:
Anti-inflammatory effect: COX-2 is overexpressed in inflamed tissue and makes the prostaglandins responsible for pain, heat, redness and swelling. Ibuprofen inhibits it effectively.
Stomach effects: gastric COX-1 makes protective PGE₂ and PGI₂. Ibuprofen suppresses them, weakening the stomach's mucosal barrier. The effect is milder than aspirin's (partly because ibuprofen does not directly damage the stomach lining as free salicylic acid does), but the risk of ulcers and bleeding with long-term use remains real.
Taking ibuprofen with food slightly delays absorption without reducing it and eases local stomach discomfort. What it does not prevent is the systemic effect on gastric COX-1, which depends on drug that has already been absorbed.
The kidney risk: prostaglandins and blood flow
Under normal conditions, kidney prostaglandins (PGE₂ and PGI₂) play only a minor role in regulating renal blood flow. But under haemodynamic stress (dehydration, heart failure, diuretic use, cirrhosis), they become critical for keeping the afferent arteriole dilated and preserving glomerular filtration.
In these situations ibuprofen can trigger acute kidney injury by removing that compensating mechanism. The risk is especially high in people over 65, in patients with chronic kidney disease, diabetes or heart failure, and during dehydration (gastroenteritis, intense exercise in the heat). Ibuprofen should not be taken without medical supervision in any of these situations.
The cardiovascular risk: an NSAID caught between two fires
All non-selective NSAIDs have a cardiovascular profile similar to that of the selective COX-2 inhibitors described in the aspirin article (Vioxx): they inhibit the production of endothelial prostacyclin (PGI₂) via COX-2 without blocking platelet TXA₂ production via COX-1 as durably as aspirin does. The net balance tilts slightly towards thrombosis.
The absolute risk is small with occasional use in healthy people. With high doses (around 2,400 mg a day) taken continuously, meta-analyses estimate that the risk of major vascular events (heart attack, stroke) rises by roughly 30–45 %. That is why long-term high-dose ibuprofen requires an assessment of the patient's cardiovascular profile.
Doses, formulations and speed of action
Ibuprofen is well absorbed by mouth (bioavailability ~80 %), with peak blood levels at 60–90 minutes. Soft-gel capsules or ibuprofen lysine and arginine salts bring the peak forward to about 30–45 minutes, hence the popularity of "fast-acting" formats for headache and period pain.
Its elimination half-life is 1.8–2 hours, which is short and explains why it has to be taken every 6–8 hours. Extended-release formulations (400–600 mg) are designed for dosing every 12 hours in chronic inflammatory conditions.
Chirality matters
Ibuprofen has one stereogenic carbon, the one carrying the methyl group on the propionic chain. In Studio you can look at the geometry of that carbon and see why its two mirror-image forms have such different pharmacological activity.
🔬 Ibuprofen in Studio
The next article covers the most unusual painkiller of all, one that is technically not an NSAID: paracetamol, whose mechanism of action is still debated 70 years after its introduction, and whose liver toxicity is the most common cause of acute liver failure in the Western world.